Application of immune checkpoint inhibitors in the treatment of recurrent or metastatic cervical cancer

doi:10.3760/cma.j.cn371439-20220511-00111

Abstract

Abstract:

Most early-stage cervical cancer patients achieve good recovery through surgical treatment and concurrent chemoradiotherapy. However, for patients with recurrent, metastatic cervical cancer, the available effective treatment is rare and the prognosis is poor. In recent years, with the development of immunotherapy, especially immune checkpoint inhibitors targeting programmed death-1 （PD-1） and its ligand （PD-L1） and cytotoxic T-lymphocyte associated protein-4 （CTLA-4）, such as pembrolizumab, nivolumab, ipilimumab, has made breakthrough progress in the treatment of recurrent or metastatic cervical cancer.

Key words: Uterine cervical neoplasms, Immunotherapy, Immune checkpoint inhibitors

Shi Yingxia, Hu Lijun, Yu Jingping. Application of immune checkpoint inhibitors in the treatment of recurrent or metastatic cervical cancer[J]. Journal of International Oncology, 2022, 49(9): 568-571.

References 17

[1]	Buskwofie A, David-West G, Clare CA. A review of cervical cancer: incidence and disparities[J]. J Natl Med Assoc, 2020, 112(2): 229-232. DOI: 10.1016/j.jnma.2020.03.002. doi: S0027-9684(20)30043-2 pmid: 32278478
[2]	Liontos M, Kyriazoglou A, Dimitriadis I, et al. Systemic therapy in cervical cancer: 30 years in review[J]. Crit Rev Oncol Hematol, 2019, 137: 9-17. DOI: 10.1016/j.critrevonc.2019.02.009. doi: S1040-8428(18)30340-8 pmid: 31014518
[3]	Wendel Naumann R, Leath CA 3rd. Advances in immunotherapy for cervical cancer[J]. Curr Opin Oncol, 2020, 32(5): 481-487. DOI: 10.1097/CCO.0000000000000663. doi: 10.1097/CCO.0000000000000663 pmid: 32740092
[4]	Frenel JS, Le Tourneau C, O'Neil B, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ⅰb KEYNOTE-028 trial[J]. J Clin Oncol, 2017, 35(36): 4035-4041. DOI: 10.1200/JCO.2017.74.5471. doi: 10.1200/JCO.2017.74.5471
[5]	Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase Ⅱ KEYNOTE-158 study[J]. J Clin Oncol, 2019, 37(17): 1470-1478. DOI: 10.1200/JCO.18.01265. doi: 10.1200/JCO.18.01265
[6]	Cohen AC, Roane BM, Leath CA. Novel therapeutics for recurrent cervical cancer: moving towards personalized therapy[J]. Drugs, 2020, 80(3): 217-227. DOI: 10.1007/s40265-019-01249-z. doi: 10.1007/s40265-019-01249-z pmid: 31939072
[7]	Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer[J]. N Engl J Med, 2021, 385(20): 1856-1867. DOI: 10.1056/NEJMoa2112435. doi: 10.1056/NEJMoa2112435
[8]	中华医学会妇科肿瘤学分会. 妇科肿瘤免疫检查点抑制剂临床应用指南[J]. 协和医学杂志, 2021, 12(6): 854-880. DOI: 10.12290/xhyxzz.2021-0683. doi: 10.12290/xhyxzz.2021-0683
[9]	Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durva-lumab after chemoradiotherapy in stage Ⅲ NSCLC[J]. N Engl J Med, 2018, 379(24): 2342-2350. DOI: 10.1056/NEJMoa1809697. doi: 10.1056/NEJMoa1809697
[10]	Lin AJ, Dehdashti F, Massad LS, et al. Long-term outcomes of cervical cancer patients treated with definitive chemoradiation following a complete metabolic response[J]. Clin Oncol (R Coll Radiol), 2021, 33(5): 300-306. DOI: 10.1016/j.clon.2021.01.010. doi: 10.1016/j.clon.2021.01.010 pmid: 33581976
[11]	Naumann RW, Hollebecque A, Meyer T, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase Ⅰ/Ⅱ CheckMate 358 trial[J]. J Clin Oncol, 2019, 37(31): 2825-2834. DOI: 10.1200/JCO.19.00739. doi: 10.1200/JCO.19.00739 pmid: 31487218
[12]	Da Silva DM, Enserro DM, Mayadev JS, et al. Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929)[J]. Clin Cancer Res, 2020, 26(21): 5621-5630. DOI: 10.1158/1078-0432.CCR-20-0776. doi: 10.1158/1078-0432.CCR-20-0776
[13]	Lheureux S, Butler MO, Clarke B, et al. Association of ipili-mumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus-related cervical carcinoma[J]. JAMA Oncol, 2018, 4(7): e173776. DOI: 10.1001/jamaoncol.2017.3776. doi: 10.1001/jamaoncol.2017.3776
[14]	Anipindi M, Smith RJ, Gilani M. Case report: immune checkpoint inhibitors as a single agent in the treatment of metastatic cervical cancer[J]. Front Oncol, 2022, 12: 856944. DOI: 10.3389/fonc.2022.856944. doi: 10.3389/fonc.2022.856944
[15]	O'Malley DM, Randall LM, Jackson CG, et al. RaPiDS (GOG-3028): randomized Phase Ⅱ study of balstilimab alone or in combination with zalifrelimab in cervical cancer[J]. Future Oncol, 2021, 17(26): 3433-3443. DOI: 10.2217/fon-2021-0529. doi: 10.2217/fon-2021-0529 pmid: 34409858
[16]	Feng CH, Mell LK, Sharabi AB, et al. Immunotherapy with radio-therapy and chemoradiotherapy for cervical cancer[J]. Semin Radiat Oncol, 2020, 30(4): 273-280. DOI: 10.1016/j.semradonc.2020.05.003. doi: 10.1016/j.semradonc.2020.05.003
[17]	Dyer BA, Feng CH, Eskander R, et al. Current status of clinical trials for cervical and uterine cancer using immunotherapy combined with radiation[J]. Int J Radiat Oncol Biol Phys, 2021, 109(2): 396-412. DOI: 10.1016/j.ijrobp.2020.09.016. doi: 10.1016/j.ijrobp.2020.09.016